Navigation Links
Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Date:10/3/2007

. The forward- looking statements should be considered in light of these risks and uncertainties. We do not undertake, and expressly disclaim any obligation, to update or alter our statements whether as a result of new information, future events or otherwise, except as required by law.


'/>"/>
SOURCE Rockwell Medical Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
5. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
8. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
9. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
10. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
11. World First Medical Treatment Announced by Researchers at Queen Mary University London and University of Leicester

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)..., , MINNEAPOLIS, Nov. 20 /PRNewswire-FirstCall...ced results for its first quarter ended September ...er diluted share, on revenues of $3,263,000. This...r diluted share, on revenues of $3,168,000 for the...he first quarter results, Biotel President and CEO...
(Date:11/20/2009)..., , FRANKLIN LAKES, N.J., Nov. 20 /PRNewswire...(NYSE: BDX ) today announced the completion of i...chigan-based company that develops and manufacture...orms. ,, In May 2009, BD and HandyLab announced...ercialize molecular assays on the HandyLab Jaguar(...
(Date:11/19/2009)..., , ARDEE, Ireland, Nov. 19 ...ed the pricing of its previously announced seconda...t a price to the public of $22.25 per share. The ... Bain Capital Partners, DLJ Merchant Banking, J.P....mas H. Lee Partners, L.P., certain other instituti...
Breaking Medicine Technology:Biotel Announced Profitable First Quarter Ended September 30, 2009 2BD Completes Acquisition of HandyLab, Inc. 2BD Completes Acquisition of HandyLab, Inc. 3Warner Chilcott Prices Secondary Equity Offering 2Warner Chilcott Prices Secondary Equity Offering 3Warner Chilcott Prices Secondary Equity Offering 4Frost 26 Sullivan Recognizes Cisbio Bioassays for Technology Innovation 12546 1Frost 26 Sullivan Recognizes Cisbio Bioassays for Technology Innovation 12546 2Frost 26 Sullivan Recognizes Cisbio Bioassays for Technology Innovation 12546 3Frost 26 Sullivan Recognizes Cisbio Bioassays for Technology Innovation 12546 4Frost 26 Sullivan Recognizes Cisbio Bioassays for Technology Innovation 12546 5Alcohol advertising self regulation not working as ads target younger drinkers 48311 1Alcohol advertising self regulation not working as ads target younger drinkers 48311 2Researchers estimate risk of transmission of Huntingtons disease to offspring among male carriers 48309 1Researchers estimate risk of transmission of Huntingtons disease to offspring among male carriers 48309 2
...uticals, Inc.,announced today that a new analysis ... Biomedical Research Institute at Harbor-UCLA Medi...of hypogonadal men with AndroGel(R),(testosterone ...rdless of,weight and body mass index (BMI). These ...ocrine Society Annual Meeting (ENDO) in San Franci...
...ONE MINERAL DENSITY, SAN DIEGO, June 17 Neurocri...ay that the elagolix 0603 Phase IIb trial,(Petal S...he last subject,completed her Week 24 study visit ...mpact of elagolix treatment on bone mineral densit...X-ray Absorptiometry (DXA) scans to,document any c...
Other Medicine Technology:New Subset Analysis of AndroGel(R) Data Highlights Efficacy - Regardless of BMI 2New Subset Analysis of AndroGel(R) Data Highlights Efficacy - Regardless of BMI 3New Subset Analysis of AndroGel(R) Data Highlights Efficacy - Regardless of BMI 4Neurocrine Biosciences Completes 'Petal Study' Treatment Phase for Endometriosis 2Neurocrine Biosciences Completes 'Petal Study' Treatment Phase for Endometriosis 3
(Date:11/23/2009)...,, CARLSBAD,Calif.,Nov.23/PRNewswire-FirstCa..., Iwouldliketostartbythankingyouforyourcontinuing...ulmomentsinourhistory.Wearetrulyattheendofthebegin...yplatform,whichwebelieveaddressesmanyoftheissuesha...ispredicatedlargelyuponthesuccessofourflagshipdrug...
(Date:11/23/2009)...,, SANDIEGO,Calif.,Nov.23/PRNewswire-FirstCa...)todayannouncedthatfourseniorexecutiveshavejoinedt...sdrivingthedevelopmentofitsobesityfranchise.Additi...dofGlobalRegulatoryAffairs;SuzanneMcDonald,HeadofM....D.,HeadofGlobalContraveProgram;andWhedyWang,Ph.D,...
(Date:11/23/2009)..., Baptist Cardiovascular ...Jackson, Miss., is proud to announce the addition ... to its latest advancement in the treatment of pat... and clinicians breathe easier. , ...-- For heart failure patients suffering from fluid...
(Date:11/23/2009)...,, NORTHANDOVER,Mass.,Nov.23/PRNewswire/--Th...stressandanxiety.Oftenthesefeelings,bothpositivean...g;andlet,sfaceit,therearelotsofopportunitiestodoso...eonepieceofmom,sapplepie,buthowmanyofusstopthere?"...ushavespentholidayseasonafterholidayseasontellingo...
(Date:11/23/2009)..., Summary: People are hir...sonalities. Personality assessments give insight i...formance. The Candidate Potential Report assesses ... summarizes the recommendation for job fit and pot...aybrook, CT (PRWEB) November 23, 2009 -- When does...
Breaking Medicine News(10 mins):Health News:Four Senior Executives Join Orexigen(R) Therapeutics Management Team 2Health News:Four Senior Executives Join Orexigen(R) Therapeutics Management Team 3Health News:Four Senior Executives Join Orexigen(R) Therapeutics Management Team 4Health News:Four Senior Executives Join Orexigen(R) Therapeutics Management Team 5Health News:Baptist Cardiovascular Services Introduces New Technology for Congestive Heart Failure Treatment 2Health News:Baptist Cardiovascular Services Introduces New Technology for Congestive Heart Failure Treatment 3Health News:Tis' the Season to Eat and Eat More! 2Health News:Candidate Potential Report Reduces Risk of Bad Hires 2Health News:Candidate Potential Report Reduces Risk of Bad Hires 3
... at University of Heidelberg in Mannheim, conclude...age more rapidly than men.// The study also states...quently as men do. This will have a revolut...d before pregnancy. It might have adverse effects ...
...ve shown that daily oral doses of Lorenzos oil can...gical disorder// called X-linked adrenoleukodystro...r Institute in Baltimore have reported that use of...e their daily doses of the oil, which is a composi...
... Drug Administration is scrutinizing the claims m...tion Bio- Germ .According to the claims made by th... can give protection from anthrax . The Bio-Germ P...ch is made from grapefruit seeds and the oil of an...
...en found to reduce the risk of cellular rejection ...ndard immunosuppression. The drug, a humanize...erleukin-2 receptor, thereby inhibiting T-cell pro...te or severe cellular rejection, hemodynamically s...
...rm of ancient Indian exercise and meditation for t...ng properties and is popularly used to relieve peo...n, trauma and anxiety in patients with breast can...ive outcome to relieve patients of pain. Now The U...
...ional study was done involving 598 068 nuclear ind...one to estimate the risk of cancer after administr...n international collaborative study to estimate th... study recruits were employed in 154 different fac...
Other Medicine News:Health News:A New Product Offering protection against anthrax 2Health News:Yoga Can Be Good For Breast Cancer Patients 2Health News:Cancer risk among nuclear industry workers 2
Lambda Fluoro 320
DELFIA Platewash
SkanStacker (110V)
...he Labcyte miniGene LW is a new plate washing syst...96 and 384 channel microplates with flat, V-shaped...with 8 or 16 channel nozzle heads. Simple LCD touc...ional plate stacker is available for the miniGene ...
Medicine Products: